Abstract
Induced pluripotent stem cells (iPSCs) share many characteristics with embryonic stem cells (ESCs), but circumvent most of the ethical issues surrounding ESCs. The use of iPSCs to treat liver diseases is gaining increasing interest. Recent studies show these iPSCs can be differentiated into the hepatic lineage and provide an accurate model for liver diseases, drug screening and drug toxicity testing. Recently, the potential application of iPSC-derived hepatocytes to be used in cell-based therapies has been explored as a novel strategy to treat human liver disease. However, the successful use of these iPSC-derived hepatocytes hinges on overcoming the inherent problems of using iPSC in cell-based therapies. Given these problems are addressed in the future, these iPSC derived hepatocytes provide a limitless supply of cells that could be used to treat liver diseases not only in screening and toxicity testing but also in cell-based therapies.
Keywords: Bio-artificial liver, cell-based therapy, disease modeling, drug screening, hepatocyte-like cells, induced pluripotent stem cells, liver disease.
Current Stem Cell Research & Therapy
Title:Potential Applications of Induced Pluripotent Stem Cells (iPSCs) in Hepatology Research
Volume: 10 Issue: 3
Author(s): Chao Sun, George S. Wilson, Jian-Gao Fan and Liang Qiao
Affiliation:
Keywords: Bio-artificial liver, cell-based therapy, disease modeling, drug screening, hepatocyte-like cells, induced pluripotent stem cells, liver disease.
Abstract: Induced pluripotent stem cells (iPSCs) share many characteristics with embryonic stem cells (ESCs), but circumvent most of the ethical issues surrounding ESCs. The use of iPSCs to treat liver diseases is gaining increasing interest. Recent studies show these iPSCs can be differentiated into the hepatic lineage and provide an accurate model for liver diseases, drug screening and drug toxicity testing. Recently, the potential application of iPSC-derived hepatocytes to be used in cell-based therapies has been explored as a novel strategy to treat human liver disease. However, the successful use of these iPSC-derived hepatocytes hinges on overcoming the inherent problems of using iPSC in cell-based therapies. Given these problems are addressed in the future, these iPSC derived hepatocytes provide a limitless supply of cells that could be used to treat liver diseases not only in screening and toxicity testing but also in cell-based therapies.
Export Options
About this article
Cite this article as:
Sun Chao, S. Wilson George, Fan Jian-Gao and Qiao Liang, Potential Applications of Induced Pluripotent Stem Cells (iPSCs) in Hepatology Research, Current Stem Cell Research & Therapy 2015; 10 (3) . https://dx.doi.org/10.2174/1574888X10666150120105946
DOI https://dx.doi.org/10.2174/1574888X10666150120105946 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research The Multidrug Resistance Mechanisms and their Interactions with the Radiopharmaceutical Probes Used for an In Vivo Detection
Current Drug Metabolism Chronopharmaceutics Based Modern Colon Specific Drug Delivery Systems
Current Drug Discovery Technologies Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design Development of Pyrazole Compounds as Antidiabetic Agent: A Review
Letters in Drug Design & Discovery The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Recent Achievements in Understanding Immune Recovery of Children Treated with HAART
Current Pediatric Reviews Laboratory Techniques for Human Viral Encephalitis Diagnosis
Infectious Disorders - Drug Targets Mechanisms of CD4 Downregulation by the Nef and Vpu Proteins of Primate Immunodeficiency Viruses
Current Molecular Medicine Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions
Current Pharmaceutical Design Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) Adaptor Protein 3BP2 and Cherubism
Current Medicinal Chemistry Advancements in Adjuvanticity of Bioactive Inorganic and Organic Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Advanced Glycation: A Novel Outlook on Atherosclerosis
Current Pharmaceutical Design High-Throughput Screening of Neuronal Cl- Channels: Why and How?
Current Neuropharmacology Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Angiotensin-(1-7), Angiotensin-Converting Enzyme 2 and Mas Receptor in Rat Polycystic Ovaries
Protein & Peptide Letters Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs